In partnering with Harvard Medical School, AbbVie plans to incorporate “fundamental biology” into new treatment development, according to an Aug. 25 announcement from the North Chicago, Ill.-based drugmaker.
“A key element of having a strong R&D organization is collaboration with top academic institutions, like Harvard Medical School, to develop therapies for patients who need them most,” Michael Severino, MD, AbbVie’s vice chairman and president said in the news release. “There is much to learn about viral diseases and the best way to treat them. By harnessing the power of collaboration, we can develop new therapeutics sooner to ensure the world is better prepared for future potential outbreaks.”
Research efforts will take place at Harvard Medical School and center on coronaviruses and viruses that lead to hemorrhagic fever. Medical researchers will explore immunity and immunopathology, host targeting, antibodies, small molecules and translational development.
More articles on pharmacy:
The 10 prescriptions most frequently filled at pharmacies
NIH to study remdesivir-esque Gilead compound as potential COVID-19 treatment
Jupiter Medical Center opens new pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
